Haemonetics Net Worth

Haemonetics Net Worth Analysis

Haemonetics Target Price Consensus

Haemonetics Target Price Projection

Haemonetics' current and average target prices are 64.80 and 110.80, respectively. The current price of Haemonetics is the price at which Haemonetics is currently trading. On the other hand, Haemonetics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Note that most analysts generally publish their price targets in research reports on specific companies, along with recommendations for the company's stock.Although price targets are often quoted in the financial news media, there could be a delay between the publication of the latest analyst outlook on Haemonetics and the information provided on this page.

Know Haemonetics' Top Institutional Investors

Note, although Haemonetics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Haemonetics' market capitalization trends

The company currently falls under 'Mid-Cap' category with a total capitalization of 3.29 B.

Project Haemonetics' profitablity

The company has Net Profit Margin of 0.09 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.19 %, which entails that for every 100 dollars of revenue, it generated $0.19 of operating income.

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Evaluate Haemonetics' management efficiency

Haemonetics has Return on Asset of 0.0633 % which means that on every $100 spent on assets, it made $0.0633 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1406 %, implying that it generated $0.1406 on every 100 dollars invested. Haemonetics' management efficiency ratios could be used to measure how well Haemonetics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Haemonetics' Return On Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.10, whereas Return On Capital Employed is forecasted to decline to 0.06. At present, Haemonetics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 99.2 M, whereas Other Assets are forecasted to decline to 1.09.

Haemonetics Corporate Filings

Haemonetics time-series forecasting models is one of many Haemonetics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Haemonetics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Haemonetics Earnings Estimation Breakdown

The calculation of Haemonetics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Haemonetics is estimated to be 1.13635 with the future projection ranging from a low of 1.125 to a high of 1.155. Please be aware that this consensus of annual earnings estimates for Haemonetics is based on EPS before non-recurring items and includes expenses related to employee stock options.

Haemonetics Earnings Projection Consensus

Haemonetics Earnings History

Earnings estimate consensus by Haemonetics analysts from Wall Street is used by the market to judge Haemonetics' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Haemonetics' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods. At present, Haemonetics' Price Earnings Ratio is projected to increase significantly based on the last few years of reporting. The current year's Net Income Applicable To Common Shares is expected to grow to about 139.3 M, whereas Common Stock Shares Outstanding is forecasted to decline to about 42.5 M.

Hype Prediction Low Estimated High 62.10 64.77 67.44 Details

Intrinsic Valuation Low Real High 58.32 75.17 77.84 Details

10 Analysts Consensus Low Target High 100.83 110.80 122.99 Details

Earnings Estimates (0) Low Projected EPS High 1.12 1.14 1.16 Details

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Haemonetics. Your research has to be compared to or analyzed against Haemonetics' peers to derive any actionable benefits. When done correctly, Haemonetics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Haemonetics. Note that many institutional investors and large investment bankers can move markets due to the volume of Haemonetics assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Haemonetics. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Haemonetics' stock price in the short term.

Haemonetics Earnings per Share Projection vs Actual

Actual Earning per Share of Haemonetics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Haemonetics predict the company's earnings will be in the future. The higher the earnings per share of Haemonetics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Haemonetics Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Haemonetics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Haemonetics should always be considered in relation to other companies to make a more educated investment decision.

Haemonetics Quarterly Analyst Estimates and Surprise Metrics

Haemonetics Corporate Directors

When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:

How To Invest In Haemonetics Details

Is Haemonetics Stock a good investment? Details

What is Haemonetics' Net Worth? Details

Largest Health Care Equipment & Supplies Companies View

Largest Health Care Equipment & Services Companies View

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Earnings Projections Details